280 related articles for article (PubMed ID: 20935218)
21. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Maurer GD; Tritschler I; Adams B; Tabatabai G; Wick W; Stupp R; Weller M
Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Zheng M; Bocangel D; Ramesh R; Ekmekcioglu S; Poindexter N; Grimm EA; Chada S
Mol Cancer Ther; 2008 Dec; 7(12):3842-51. PubMed ID: 19056673
[TBL] [Abstract][Full Text] [Related]
23. Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
Jiang G; Jiang AJ; Xin Y; Li LT; Cheng Q; Zheng JN
Mol Biol Rep; 2014 Oct; 41(10):6659-65. PubMed ID: 24990698
[TBL] [Abstract][Full Text] [Related]
24. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
25. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
26. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
27. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Qiu ZK; Shen D; Chen YS; Yang QY; Guo CC; Feng BH; Chen ZP
Chin J Cancer; 2014 Feb; 33(2):115-22. PubMed ID: 23958055
[TBL] [Abstract][Full Text] [Related]
28. Genomic and molecular profiling predicts response to temozolomide in melanoma.
Augustine CK; Yoo JS; Potti A; Yoshimoto Y; Zipfel PA; Friedman HS; Nevins JR; Ali-Osman F; Tyler DS
Clin Cancer Res; 2009 Jan; 15(2):502-10. PubMed ID: 19147755
[TBL] [Abstract][Full Text] [Related]
29. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
van Nifterik KA; van den Berg J; van der Meide WF; Ameziane N; Wedekind LE; Steenbergen RD; Leenstra S; Lafleur MV; Slotman BJ; Stalpers LJ; Sminia P
Br J Cancer; 2010 Jun; 103(1):29-35. PubMed ID: 20517307
[TBL] [Abstract][Full Text] [Related]
30. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
[TBL] [Abstract][Full Text] [Related]
31. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
[TBL] [Abstract][Full Text] [Related]
32. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
33. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
34. O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Fontijn D; Adema AD; Bhakat KK; Pinedo HM; Peters GJ; Boven E
Mol Cancer Ther; 2007 Oct; 6(10):2807-15. PubMed ID: 17938272
[TBL] [Abstract][Full Text] [Related]
35. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
Wang X; Chen JX; Liu YH; You C; Mao Q
Neurol Sci; 2013 Aug; 34(8):1421-8. PubMed ID: 23224642
[TBL] [Abstract][Full Text] [Related]
36. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Natsume A; Ishii D; Wakabayashi T; Tsuno T; Hatano H; Mizuno M; Yoshida J
Cancer Res; 2005 Sep; 65(17):7573-9. PubMed ID: 16140920
[TBL] [Abstract][Full Text] [Related]
37. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
[TBL] [Abstract][Full Text] [Related]
38. In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Kreth S; Limbeck E; Hinske LC; Schütz SV; Thon N; Hoefig K; Egensperger R; Kreth FW
Acta Neuropathol; 2013 May; 125(5):671-81. PubMed ID: 23340988
[TBL] [Abstract][Full Text] [Related]
39. Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells.
Kewitz S; Stiefel M; Kramm CM; Staege MS
Leuk Res; 2014 Jan; 38(1):138-43. PubMed ID: 24284332
[TBL] [Abstract][Full Text] [Related]
40. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]